Cate Lockhart, PharmD, PhD, explains the similarities and differences between generics and biosimilars.
Transcript:
What are some ways in which biosimilars are like generics?
That’s true they’re not generics, but I think what people fail to realize or fully appreciate is that “no clinically relevant” difference. So, my PhD is in pharmaceutics so from a pharmacokinetics stand point a biologic— the innovator biologic– has quite a lot of variation within a single batch from lot to lot. But there’s really– you can keep taking that same innovator biologic, even though it’s going to be a little different than the last dose that you had, probably, or there’s a risk or chance there would be some level of variation. It’s probably not a lot of variation, but it is there, and you don’t see a clinically different response.
It’s the same story with biosimilars. There’s going to be variation, there’s going to be variation within the biosimilar lot. There’s going to be variation between it and the reference product to some extent within the threshold, but the exact same thing is true with generic drugs. There’s less variability within a lot in generic drugs, but the variation between the original branded small molecule drug and the generic is still within the threshold. So, it’s not identical ultimately, [but] there is a threshold and it’s really the same story with biologics that there’s variation anyway, but it doesn’t manifest itself in any clinically relevant way.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.